Following in the footsteps of rival Moderna, BioNTech has started developing its own mRNA-based vaccine for mpox — building upon its work in COVID-19 and malaria. The company is launching a Phase 1/2 trial to test the vaccine. (Endpoints News)
Novo Nordisk hired private contract manufacturer PCI Pharma Services to handle assembly and packaging of Wegovy, a source familiar with the matter said. This comes as the drugmaker races to boost output of the weight-loss drug to meet demand. (Reuters)
Danish medical dermatology company LEO Pharma will acquire Timber Pharmaceuticals in a deal worth $36 million. The deal includes contingent value rights worth up to $22 million in milestones for Timber’s congenital ichthyosis candidate, TMB-001. (MarketWatch)
As the fall COVID-19 vaccination campaign begins, public health officials at the FDA and the Centers for Disease Control and Prevention said they hope to change the terminology from “boosters” to simply “updated vaccines.” That’s because annual COVID-19 vaccines should be seen as yearly shots from now on, as opposed to boosters, experts say. (CBS News)
Johnson & Johnson’s Kenvue spin off is unlikely to drive market-beating returns, according to an analyst. J&J achieved a steady 3.3% revenue growth over the past decade with a stable 26.6% average operating margin, showing resilience even during market turbulence. (Seeking Alpha)
